Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

Abstract Background The PI3K/AKT/mTOR (PAM) pathway is a key regulator of tumor therapy resistance. We investigated M2698, an oral p70S6K/AKT dual inhibitor, in patients with advanced cancer who failed standard therapies. Methods M2698 was administered as monotherapy (escalation, 15–380 mg daily; fo...

Full description

Bibliographic Details
Main Authors: Apostolia-Maria Tsimberidou, Jamie V. Shaw, Dejan Juric, Claire Verschraegen, Amy M. Weise, John Sarantopoulos, Gilberto Lopes, John Nemunaitis, Monica Mita, Haeseong Park, Barbara Ellers-Lenz, Hui Tian, Wenyuan Xiong, Remigiusz Kaleta, Razelle Kurzrock
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Journal of Hematology & Oncology
Subjects:
AKT
PI3K
p70S6K
Phase I
Advanced cancer
Clinical trial
Online Access:https://doi.org/10.1186/s13045-021-01132-z

Internet

https://doi.org/10.1186/s13045-021-01132-z

Similar Items